Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR ) 41.15 +3.29 (+8.69%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Structure Therapeutics Inc. - American Depositary Shares < Previous 1 2 3 4 5 Next > Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar June 14, 2024 The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug. Via Investor's Business Daily Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy? June 11, 2024 Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you. Via The Motley Fool Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet June 10, 2024 The company is focusing on obesity treatment after its glaucoma drug failed. Via Investor's Business Daily Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy? June 09, 2024 Structure Therapeutics has a long way to go before beating Wegovy. Via The Motley Fool Top Names Performance Update - Saturday, June 8 June 08, 2024 I usually show the performance of the top names cohort from six months earlier, but we didn’t have the full, six-month performance of our Dec. 7 top names cohort yet, so here is a stand-alone... Via Talk Markets Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million June 08, 2024 Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... Via Talk Markets Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares June 07, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering June 05, 2024 From Structure Therapeutics Inc. Via GlobeNewswire The 3 Most Undervalued Biotech Stocks to Buy in June 2024 June 04, 2024 https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate Via InvestorPlace Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants June 03, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says June 03, 2024 Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target Via Benzinga Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 03, 2024 Via Benzinga Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results June 03, 2024 Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug. Via Investor's Business Daily 10 Health Care Stocks With Whale Alerts In Today's Session June 03, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session June 03, 2024 Via Benzinga Obesity Data From Structure Therapeutics Shows Potential For Weight Loss Drug Candidate June 03, 2024 Structure Therapeutics announces Phase 2a results for GSBR-1290, showing significant weight loss in obesity study. Via Benzinga Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday June 03, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session June 03, 2024 Via Benzinga Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 June 03, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing May 31, 2024 Sometimes the next big thing stocks to buy and hold are flying well under the radar. Here are three to consider. Via InvestorPlace This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan May 21, 2024 The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. Via Benzinga GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q1 2024 May 09, 2024 GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights May 09, 2024 From Structure Therapeutics Inc. Via GlobeNewswire 7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025 May 09, 2024 The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. Via InvestorPlace 3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains April 24, 2024 These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. Via InvestorPlace 7 Small-Cap Stocks that Wall Street Loves for Good Reason March 30, 2024 As small-cap stocks start to catch up to the market rally, it's time to look at seven small-cap stocks that Wall Street loves. Via InvestorPlace GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023 March 15, 2024 GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference March 08, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights March 08, 2024 From Structure Therapeutics Inc. Via GlobeNewswire The Best-Performing U.S. IPOs Of 2023 February 04, 2024 In 2023, there were 154 IPOs on the U.S. stock market. Here is a look at some of the best initial public offerings from last year. Via Talk Markets < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
